Company intelligence / Profile preview

Itamar Medical

Ownership: Private
Employees: ~184
Development stage: Commercial

Overview

Itamar Medical has commercialized FDA-cleared non-invasive diagnostic devices for home and clinical use in the detection of sleep-disordered breathing and early cardiovascular risk. Its WatchPAT device provides a validated alternative to polysomnography for diagnosing obstructive and central sleep apnea. The company’s technologies are widely adopted in the U.S., Europe, Japan, and other major markets. Clinical studies have demonstrated high correlation with gold-standard tests for both cardiac and respiratory applications.

Therapeutic areas: PulmonologyCardiovascular
Modalities: DeviceDigital health platform (for sleep apnea management)Non-pharmacological therapy (diagnostic)
Industry: Physiological Monitoring

Partnerships

SoClean Inc. – exclusive direct-to-consumer partnership for WatchPAT ONE in the U.S.

Beyond the preview

Go deeper on Itamar Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Itamar Medical.

Explore the full profile